Focus,
amplified.

What Semax is.

Semax is a seven-amino-acid analog of the natural ACTH(4-10) sequence — the part of adrenocorticotropic hormone responsible for its non-stress neurotrophic effects, with the corticotropic activity stripped away. The extra Pro-Gly-Pro tail at the C-terminus stabilizes the peptide so it can actually do its job before being metabolized.

The compound has been used clinically in Russia and several CIS countries since the early 1990s — primarily for stroke recovery, transient ischemic attack, and various cognitive indications. It remains on the Russian List of Vital and Essential Drugs.

In the United States, it is available only as a compounded peptide under prescription; it is not FDA-approved as a finished drug.

The mechanism (in plain English).

Semax appears to work primarily by upregulating BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the hippocampus and prefrontal cortex. BDNF is the protein your brain uses to maintain and form synaptic connections — exercise raises it; chronic stress lowers it.

That mechanism is why patients tend to feel Semax not as a stimulant but as a "focus floor" — the work feels less effortful, fatigue arrives later, and recovery from a hard mental day comes faster.

What patients actually report.

• Day 1. Most patients feel a subtle "filter" effect within an hour of intranasal dose — distractions register but don't pull as hard.
• Week 1. Better tolerance for long meetings, deep work, screen-heavy days. Sleep is unchanged or slightly better.
• Week 4. Patients describe being able to "shift gears" between tasks more cleanly — what changes most is the cost of context-switching, not raw IQ.

Some patients describe a clear effect, others describe nothing at all. We don't oversell — about 25–30% of patients in our intake notes consider it "not for them" by week 4. We don't lock you in.

Side-effect profile.

• Mild headache in the first 2–3 days for a minority of patients.
• Transient nasal irritation with intranasal use.
• Vivid dreams — common but typically welcomed.
• Over-stimulation if dosed late in the day. Most patients dose mornings only.

Not for use during pregnancy. Patients with seizure disorders or significant psychiatric history warrant additional clinician review; neuropeptides interact with mood and threshold pathways in ways that aren't uniform across patients.

How a typical Pepra protocol runs.

The most common Pepra protocol: 1–2 sprays per nostril, twice daily, mornings and early afternoons, for 4 weeks. Patients often re-cycle 1–2 months later for a second 4-week run. Continuous daily use beyond 8 weeks is rare; we re-evaluate before extending.

For patients who tried intranasal and didn't feel an effect, we sometimes switch to subcutaneous Semax at 250–500 mcg daily — slightly stronger, but more committal. Your prescriber decides which is right.